Abstract |
A number of recent studies revealed that successful treatment of the patients with MDR/ XDR- TB was not achieved due to high resistant rates to many second-line drugs such as kanamycin and prothionamide including poor adherence of the lengthy treatment. Many new drugs and compounds such as benzothiazinones, meropenem, PA-824, isoflavonoids, rhein, PNU-100480, TMC207, SQ109, OPC-67683, AZD5847, and linezolid are currently in development pipeline. According to very few patents in new compounds and drugs against MDR/XDRMycobacterium tuberculosis bacilli have been currently introduced, so inventors must be encouraged to contribute to this area worldwide.
|
Authors | Attapon Cheepsattayakorn, Ruangrong Cheepsattayakorn |
Journal | Recent patents on anti-infective drug discovery
(Recent Pat Antiinfect Drug Discov)
Vol. 7
Issue 2
Pg. 141-56
(Aug 2012)
ISSN: 2212-4071 [Electronic] Netherlands |
PMID | 22670838
(Publication Type: Journal Article, Review)
|
Chemical References |
|
Topics |
- Animals
- Antitubercular Agents
(pharmacology, therapeutic use)
- Extensively Drug-Resistant Tuberculosis
(drug therapy)
- Humans
- Mycobacterium tuberculosis
(drug effects)
- Patents as Topic
|